[Comment] miR-16: expanding the range of molecular targets in mesothelioma

04:04 EDT 2 Sep 2017 | The Lancet

Malignant mesothelioma is a cancer caused by exposure to asbestos. It has a devastating prognosis, and its incidence has increased substantially in high-income countries during the past three decades. Systemic therapy comprising cisplatin and pemetrexed remains the only approved standard of care, a therapeutic plateau that has endured for more than 10 years. New, effective therapies based on an understanding of the underlying biology are clearly needed. By contrast with many other cancers, including lung cancer and melanoma, somatic mutations in oncogenic kinases have not been identified in the genomic landscape of mesotheliomas.

Original Article: [Comment] miR-16: expanding the range of molecular targets in mesothelioma


More From BioPortfolio on "[Comment] miR-16: expanding the range of molecular targets in mesothelioma"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....